CO Oxidation Catalyzed by Oxide-Supported Au25(SR)18 Nanoclusters and Identification of Perimeter Sites as Active Centers

CO Oxidation Catalyzed by Oxide-Supported Au25(SR)18 Nanoclusters and Identification of Perimeter Sites as Active Center

低能He~(2+)-He碰撞体系转移电离机理的实验研究；Experimental investigation of transfer ionization mechanism in slow He~(2+)-He collisions

利用冷靶反冲离子动量谱仪,对低能He2+-He碰撞反应中产生的反冲靶离子和炮弹离子进行了符合测量,根据反冲靶离子的动量,研究了转移电离过程中的电荷转移机理.实验结果表明:在20—40keV能量范围内,靶原子上的一个电子俘获到炮弹离子的基态,另一个电子直接发射到靶的连续态的直接电离及另一个电子俘获到炮弹离子的连续态的过程(ECC)是最主要的转移电离机理,且ECC过程主要发生在大碰撞参数条件下;炮弹离子俘获两个电子处在双激发态的自电离过程的贡献很小

低能He~(2+)-He反应中单电子俘获微分散射过程的实验研究

利用冷靶反冲离子动量谱仪装置系统研究了20—40keVHe2+-He碰撞体系的态选择单电子俘获过程,实验获得了单电子俘获过程的态选择截面以及角微分截面.在所研究的能区范围,电子俘获到L壳层的截面最大,为主要的反应道,这与分子库仑过垒模型的反应窗理论的预测一致.实验测量的态选择截面与原子轨道紧耦合的计算结果很好地符合,与光谱方法的测量结果存在一定的差别,主要原因是光谱方法不能测量完整的反应通道信息.实验结果表明,总角微分截面在小角度范围主要来源于电子俘获到基态的贡献,在大角度范围主要来自电子俘获到激发态的贡献;电子俘获到基态的和激发态的角微分截面均出现振荡结构,这种振荡来源于电子俘获反应中分子轨道之间的相干效应.实验测量的角微分截面与其他实验和紧耦合方法的计算结果进行了比较和分析

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials